PCR-heteroduplex by grouping: Rapid screening carrier method for cystic fibrosis F508del mutation in Colombia;PCR-heterodúplex por agrupamiento: Implementación de un método de identificación de portadores de la mutación más común causal de fibrosis quística en Colombia

Colombia Medica

Volumn 37, Issue 3, 2006, Pages 176-182

  Jay, Lina Manuela ^a   Mateus, Heidi ^b   Fonseca, Dora ^b   Restrepo, Carlos Martín ^b   Keyeux, Genoveva ^c  

^a UNIVERSIDAD DISTRITAL FRANCISCO JOSÉ DE CALDAS   (Colombia)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

CFTR; Colombia; Cystic fibrosis; Genetic screening; Heteroduplex analysis

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BLOOD SAMPLING; COLOMBIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CARRIER; EARLY DIAGNOSIS; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HETERODUPLEX ANALYSIS; HETEROZYGOTE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; POLYMERASE CHAIN REACTION; RELIABILITY; REPRODUCIBILITY; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 33748667315     PISSN: 16579534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Riordan J, Kerem B, Rommens JM. Identification of cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1072.
2. Fibrosis genetic analysis consortium. Online cystic fibrosis mutation data. [fecha de acceso noviembre 16, 2005]. URL disponible en: http://www.genet.sickkids.on.ca/cftr/
3. Bobadilla J, Macek M, Fine J, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
4. Lemna W, Feldman G, Kerem B. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med 1990; 322: 291-296.
5. Collazo T, Magarino C, Chávez R, Suardiaz B, Gispert S, Gómez M, et al. Frequency of delta-F508 mutation and XV2C/KM19 haplotypes in Cuban cystic fibrosis families. Hum Hered 1995; 45: 55-57.
6. Orozco L, Velásquez R, Zielenski J. Spectum of CFTR mutations in Mexican cystic fibrosis patients: identification of five novel mutations (W1098C, 846delT, P750L, 4160insGGGG and 297-G′!A). Hum Genet 2002; 106: 360-365.
7. Venegas PB, Novak JM, Oscar CA, Sánchez FL, Gutiérrez IG, Rivera JM, et al. Cystic fibrosis mutations in Costa Rica. Hum Biol 2003; 75: 179-188.
8. Visich A, Zielenski J, Castanos C. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. Clin Genet 2002; 61: 207-213. Erratum in: Clin Genet 2002; 62: 343.
9. Grebe T, Seltzer WK, de Marchi X. Genetic analysis of Hispanic individuals with cystic fibrosis. Am J Hum Genet 1994; 54: 443-446.
10. Restrepo CM, Pineda L, Rojas-Martínez A. CFTR mutations in three Latin American countries. Am J Med Genet 2000; 91: 277-279.
11. Keyeux G, Sánchez D, Garavito P. Estudios moleculares en pacientes colombianos con fibrosis quística. Acta Med Colomb 1997; 22: 167-173.
12. Keyeux G, Rodas C, Bienvenu T. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. Hum Mutat 2003; 644: 1-7.
13. Raskin S, Phillips JA, Krishnamani MR, Vnencak-Jones C, Parker RA, Rozov T, et al. Cystic fibrosis genotyping by direct PCR analysis of Guthrie blood Sports. Am J Med Genet 1993; 46: 665-669.
14. Makowski GS, Davis EL, Hopfer SM. Enhanced direct amplification of Guthrie card DNA following selective elution of PCR inhibitors. Nucleic Acids Res 1995; 23: 3788-3789.
15. Cuckle HS, Wald N. Test using single markers. In: Antenatal and neonatal screening. 2nd ed. Wold N (ed.). Oxford: Oxford University Press; 2000. p. 3-22.
16. Nagamine C, Chan K, Lau Y-F C. A PCR artifact: Generation of heteroduplex. Am J Hum Genet 1989; 45: 337-339.
17. Anglani F, Picci L, Camporese C, Zacchello F. Heteroduplex formation in polymerase chain reaction. Am J Hum Genet 1990; 47: 169-170.
18. National Committee for Clinical Laboratory Standards. Blood collection on filter paper for neonatal screening programs. 2nd ed. (document LA4-A2). Approved standard. Vol. 12, No 13. Villanova: NCCLS; 1992.
19. Huber KH, Mirkovic B, Nersesian R, Myers A, Saiki R, Bauer K. Survey of CF mutations in the clinical laboratory. BMC Clin Pathol 2002; 2: 1-8.
20. Schoos R, Verloes A, Bourguignon JP, Koulischer L. Programs of systematic screening in neonatology. Pharmaco-economic aspects. Rev Med Liege 1998; 53: 311-315.